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Abstract
Purpose The present study aimed to assess the cost
effectiveness of concomitant proton pump inhibitor (PPI)
treatment in low-dose acetylsalicylic acid (LDASA) users
at risk of upper gastrointestinal (UGI) adverse effects as
compared with no PPI co-medication with attention to the
age-dependent influence of PPI-induced adverse effects.
Methods We used a Markov model to compare the strategy
of PPI co-medication with no PPI co-medication in older
LDASA users at risk of UGI adverse effects. As PPIs
reduce the risk of UGI bleeding and dyspepsia, these risk
factors were modelled together with PPI adverse effects for
LDASA users 60–69, 70–79 (base case) and 80 years and
older. Incremental cost-utility ratios (ICURs) were calcu-
lated as cost per quality-adjusted life-year (QALY) gained
per age category. Furthermore, a budget impact analysis
assessed the expected changes in expenditure of the Dutch
healthcare system following the adoption of PPI co-treat-
ment in all LDASA users potentially at risk of UGI adverse
effects.
Results PPI co-treatment of 70- to 79-year-old LDASA
users, as compared with no PPI, resulted in incremental
costs of €100.51 at incremental effects of 0.007 QALYs
with an ICUR of €14,671/QALY. ICURs for 60- to
69-year-old LDASA users were €13,264/QALY and
€64,121/QALY for patients 80 years and older. Initiation
of PPI co-treatment for all Dutch LDASA users of 60 years
and older at risk of UGI adverse effects but not prescribed a
PPI (19%) would have cost €1,280,478 in the first year
(year 2013 values).
Conclusions PPI co-medication in LDASA users at risk of
UGI adverse effects is generally cost effective. However,
this strategy becomes less cost effective with higher age,
particularly in patients aged 80 years and older, mainly due
to the increased risks of PPI-induced adverse effects.
Key Points
Adding a proton pump inhibitor (PPI) in low-dose
acetylsalicylic acid users at risk of upper
gastrointestinal adverse effects was cost effective in
all cases for a threshold value of €64,121.
With higher age and including the risk of adverse
effects, adding a PPI became less cost effective,
mainly due to the increased risks of PPI-induced
adverse effects.
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1 Introduction
Upper gastrointestinal (UGI) adverse effects caused by
low-dose acetylsalicylic acid (LDASA) often result in
hospital admissions [1, 2]. Proton pump inhibitors (PPIs)
are effective in preventing these adverse effects [3–5].
Therefore, Dutch guidelines recommend PPI co-treatment
in LDASA users older than 80 years and in those between
70 and 80 years who take additional co-medication that
increases the risk of UGI adverse effects. In LDASA users
between 60 and 70 years with two additional risk factors
due to co-medication or with a medical history of an
ulceration, PPI co-treatment is also indicated [6, 7].
However, for various reasons, these recommendations
appear to have been implemented only to a limited extent
to date [6, 8]. At the time they were issued (2009) only
two-thirds of the patients at risk were prescribed any form
of gastroprotective medication [9]. Since LDASA is gen-
erally intended for a lifelong use, patients at risk should use
PPIs for long-term gastroprotection as well. However, the
prolonged use of PPIs has been associated with adverse
effects such as osteoporosis and hip fractures [10–17],
pneumonia [18–23], and campylobacteriosis [24].
Although the actual risk increases were found to be modest
and might have been confounded [13, 23, 25], the US Food
and Drug Administration (FDA) has labelled PPIs as hav-
ing a risk of osteoporosis [26]. Although the FDA has no
authority in Europe, US recommendations get attention in
medical and pharmaceutical journals available in the
Netherlands and therefore may have consequences outside
the regulatory scope of the FDA. Recommendations to use
PPIs are based on clinical evidence, but as yet there are
limited data on the cost effectiveness of PPI co-treatment.
Since cheaper generic preparations have become widely
available, PPI costs used in earlier analyses, comparing
strategies of LDASA treatment with and without PPI co-
medication to no LDASA treatment for primary or sec-
ondary prevention, are no longer representative [27, 28].
Accordingly, De Groot et al. [29] recently concluded that
PPI co-treatment was likely to be cost effective. Since the
risk of developing UGI adverse effects and the mortality
risk have been found to differ in an age-dependent manner,
the present recommendations to start gastroprotection in
LDASA users include various age categories [6]. More-
over, recent advances in knowledge have increasingly
drawn attention to the potential burden of PPI adverse
effects [10–25]. The present study therefore aimed to
assess the cost effectiveness of the strategy of PPI co-
treatment compared with no PPI use in LDASA users at
risk of UGI adverse effects, paying specific attention to
potential adverse effects due to PPI use in patients of dif-
ferent ages. In addition, we estimated the costs of treating
all LDASA users in the Netherlands who are at risk of UGI
adverse effects and are currently not receiving PPI co-
medication.
2 Methods
2.1 Model Framework
In order to calculate the cost effectiveness of PPI co-
medication in LDASA users, a Markov model was devel-
oped using Microsoft Office Excel 2007 (Microsoft
Corp., Redmond, WA, USA). The model compared the
strategies of PPI co-medication with no PPI co-treatment in
LDASA users from a healthcare perspective.
The model structure is shown in Fig. 1. A hypothetical
cohort of 1000 patients entered the model in a health state
without UGI symptoms. Through a series of 3-monthMarkov
transition cycles, the cohort was followed over a 5-year time
horizon. In a 3-month cycle, patients could stay in this health
state or develop dyspepsia, gastrointestinal bleeding, hip
fractures, pneumonia ormight die. Patients could return to the
‘healthy state’ after dyspepsia occurred, but they transferred to
a ‘post’ health state after gastrointestinal bleeding. From a
‘post’ state, subjects may still develop other complications
(e.g. dyspepsia or recurrent gastrointestinal bleeding) or hip
fracture and pneumonia, but could never return to the ‘healthy
state’. Their risk for re-bleeding and dyspepsia increased
under the model assumptions. We chose a cycle length of
3 months because of the rather short duration of the modelled
adverse effects. After 3 months patients should be able to
transit to a post-adverse effect health state and have a proba-
bility of developing another adverse effect. For the strategy
without PPI co-medication, for subjects in the ‘post’ state
Initiation of PPI treatment was assumed which resulted in a
risk reduction of UGI adverse effects and costs. We assumed
there was continuous use of a PPI during 5 years at a com-
pliance rate of 68%, to reflect clinical practice [30]. Full
adherence was assumed for LDASA.
2.2 Model Parameters
Model parameters were retrieved from recent studies
addressing LDASA use with PPI co-medication that had the
parameters and source clearly stated, preferably conducted
in the Netherlands. Most parameters for the model could be
derived from two different studies by De Groot et al.
[29, 30] describing risk parameters, cost estimates and
utilities related to UGI adverse effects. These models were
identified by searching for models comparing the strategy of
PPI co-medication with no PPI in LDASA/non-steroidal
anti-inflammatory drug (NSAID) users that were published
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over the last 10 years, and contained the most recently
published scientific data. As the transition probabilities in
these studies were for 1-year cycles, they were transformed
into 3-month specific probabilities [31]. Whenever possible,
parameter risks were modified for effects related to
increasing age (probabilities of developing a peptic ulcer
bleeding [PUB], of pneumonia due to PPI, of hip fracture
due to PPI; the general mortality rate; and the chance of
PUB while using LDASA). The utilities related to the dif-
ferent health states were used to calculate quality-adjusted
life-years (QALYs) [32]. Most of the cost estimates used by
De Groot et al. [29, 30] were used except for medication
costs, which were collected from the Dutch National Health
Care Institute [33]. Parameters and costs retrieved from
these studies were updated when necessary; these are all
given in Appendix A.
The risk of hip fractures and pneumonia due to PPI use
was estimated in two steps. First, information on incidence
rates in the general population for hip fracture and pneu-
monia was derived from recent Statistics Netherlands data
[34]. Second, these rates were multiplied by PPI-specific
risk ratios collected from the literature on increased risks of
hip fracture [10] and pneumonia [18]. Cost estimates for
the health states of pneumonia [35] and hip fracture [36]
were derived from the literature (Appendix A).
2.3 Analysis
2.3.1 Base-Case Analysis
The base case cohort of 70- to 79-year-old patients con-
sisted of 1000 LDASA users. Costs were discounted at an
annual rate of 4% and utilities at an annual rate of 1.5%
according to the Dutch guidelines for pharmacoeconomic
evaluation [37]. Parameter uncertainty was examined with
Monte-Carlo simulations of 5000 iterations. Within each
iteration, values for the model parameters in question were
randomly selected from their distribution [32], charac-
terised by 95% confidence intervals (CIs) and standard
errors [29, 30]: beta distributions were used for probability
and utilities, gamma distributions for costs and lognormal
distributions for risk ratios [31].
Based on Monte-Carlo simulations, the difference in
costs and QALYs between the strategy of using PPI co-
medication and no PPI co-medication was expressed as an
incremental cost-utility ratio (ICUR) for each iteration. Of
the 5000 iterations, the 2.5th and 97.5th percentiles were
determined for the incremental costs and effects and pre-
sented as scatter plots of incremental costs and effects, and
cost-effectiveness acceptability (CEA) curves. CEA curves
were constructed to estimate the probability that PPI co-
medication was cost effective given different cost-effec-
tiveness thresholds. In addition to the base case, ICURs
were also estimated for LDASA users 60–69 years old and
80 years old and above, according to the guideline age
thresholds for the risk of UGI adverse effects [6, 7].
2.3.2 Sensitivity Analysis
One-way sensitivity analysis was performed to assess the
effects of the different model parameters on the cost
effectiveness of PPI co-medication. They are shown in
tornado diagrams for the effect of parameter values of the
5th and 95th percentiles on the net monetary benefit
(NMB). The incremental NMB shows the difference
between PPI co-medication and no PPI use in LDASA
users at risk as a monetary value. This was calculated as the
maximum amount an individual is willing to pay for a unit
Healthy
GI bleedingDyspepsia
Death
Post-GI 
bleeding
Dyspepsia -
post-GI 
bleeding
Hip fracture
Pneumonia
Fig. 1 Markov model structure
for the effects of proton pump
inhibitor co-medication in low-
dose acetylsalicylic acid users at
increased upper gastrointestinal
risk. A cohort of 1000 patients
was modelled for a period of
5 years. Each patient started in a
healthy state, and in each
3-month cycle patients could
enter one of the other health
states (dyspepsia,
gastrointestinal bleeding, hip
fracture, pneumonia or death) or
stay healthy. Patients could
develop a hip fracture or
pneumonia after each health
state. GI gastrointestinal
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or effect (QALY), the so-called willingness to pay (WTP),
minus the difference in costs of both strategies [32]. The
WTP assumed here was €30,000, as an example, to
showcase the influences of the parameters.
2.3.3 Scenario Analysis
Furthermore, scenario analyses with and without costs for
adverse effects were performed. In these different scenar-
ios, pneumonia and hip fracture were taken into account
separately or not at all. Incremental costs and effects and
subsequent ICURs were calculated per scenario. Scenario
analyses were also performed for the discount rates, where
both costs and effects were discounted at the same rate
[32], and for the compliance rate in order to estimate the
influence of both parameters. For both parameters, there is
considerable controversy about their weight and whether
they should be included or not. Therefore, their influence is
investigated in these scenarios.
2.3.4 Budget Impact Analysis
Finally, a budget impact analysis (BIA) was performed
according to international guidelines [37, 38] to calculate
the costs of PPI co-treatment in LDASA users at risk but
without actual gastroprotective PPI co-medication. In order
to calculate the budget impact, the cost-effectiveness
model of this study was used. Therefore, this BIA was
performed from a healthcare perspective (only healthcare
costs included) with a time horizon of 1 year. With this
model the costs of the usual care without PPIs, and sub-
sequently the costs related to care with PPI use, could be
calculated. The difference in costs was used in the BIA.
Subsequently, the number of potential PPI users in the
Dutch population was estimated on the basis of Dutch
Foundation of Pharmaceutical Statistics (SFK) data. SFK
collects dispensing data from 95% of the 1980 Dutch
community pharmacies. These data contain detailed
information on the drugs dispensed, including the codes
from the Anatomic Therapeutic Chemical (ATC) system of
the World Health Organization [39], prescribed dose, and
amount dispensed. Information on patient sex and year of
birth is also available. Medication of a specific patient over
time was tracked within an individual pharmacy by a
unique anonymous code for each patient. Drug exposure
episodes were calculated by dividing the number of drug
units dispensed by the prescribed daily dose. Increased risk
of UGI adverse effects was assessed according to the rec-
ommendations for LDASA users of 80 years or older, those
between 70 and 80 years using other antithrombotic agents,
oral corticosteroids, selective serotonin reuptake inhibitors
or spironolactone co-medication, and for LDASA users
between 60 and 70 years with two additional risk factors
from co-morbidity or co-medication [6]. The following
ATC codes were used for the different drug classes:
LDASA (B01AC06, B01AC08 and B01AC30); other
antithrombotics—clopidogrel (B01AC04), prasugrel
(B01AC22), ticagrelor (B01AC24) and coumarins
(B01AA); glucocorticosteroids for oral use (H02AB);
selective serotonin reuptake inhibitors (N06AB, N06AX16,
N06AX05 and N06AX21); spironolactone (C03DA01);
and PPIs (A02BC).
The BIA was first calculated per age category, because
at different ages different costs were made due to a dif-
ferential use of health resources. Eventually, the total sum
of all categories was considered as the budget impact
related to implementation of PPIs.
3 Results
Table 1 gives the results of the cost-effectiveness analysis
for the complete model for LDASA users 60–69, 70–79
and C80 years. The results of the base case show that PPI
co-medication achieves 0.007 QALYs at a cost of €100.51
compared with no PPI co-medication in LDASA users.
This resulted in an ICUR of €14,671 per QALY gained.
ICURs for PPI co-medication compared with no PPI use in
the 60–69 and 80 years and older groups amounted to
€13,264 and €64,121, respectively.
Figure 2 gives the results of the Monte-Carlo simula-
tions for LDASA users for the three age categories within
the different panels as scatterplots and CEA curves. Most
dots are in the north-eastern quadrant for the base case of
70–79 years old,, meaning a positive effect (gain in
QALY) with positive costs (increased costs). The CEA for
70- to 79-year-old LDASA users shows that PPI co-med-
ication has a 50% chance of being a cost-effective strategy
at a WTP threshold of €19,000 per QALY gained (Fig. 2d).
For the subgroup of 80 years and older LDASA users, most
dots on the scatter plots also lay in the north-eastern
quadrant. In the results for 70- to 80-year-old users, the
dots lay higher and more to the left, which means higher
incremental costs and fewer incremental effects gained by
adding a PPI. This resulted in a WTP threshold of €80,000
for PPI co-medication with a 50% chance of being cost
effective on the CEA curve (Fig. 2f).
The results of the scenario analyses related to the adverse
effects are shown in Table 1. PPI co-medication was always
cost effective at a WTP threshold of €64,121, even when
adverse effects were taken into account. However, the ICUR
was higher in the model accounting for adverse effects for
all age categories. In cases where adverse effects were not
taken into account, PPI co-medication ‘dominated’ (lower
costs and more effects) the strategy of not adding a PPI for
LDASA users 80 years and older.
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When the discount rates for both costs and effects were
4%, the ICUR of the base case was €15,792. For the age
categories of 60–69 years and 80 years and older, the
ICURs were €14,241 and €68,294, respectively. If the
compliance rate was varied between the extremes of the
95% CI (20% and 100%), the ICURs for the base case were
€73,186 and €9391, respectively.
In the tornado diagrams (Fig. 3), the ranges, and sub-
sequently the influence of the different adverse effects on
the incremental NMB, are shown for the base case as well
as for 80-year-old LDASA users. For 80-year-old LDASA
users the estimates for the costs and risks of hip fracture
became important influencers of the incremental NMB as
compared with the base case.
Table 2 gives the results from the BIA of adding PPIs to
all LDASA users at risk in the Netherlands who were not
concomitantly using a PPI. According to SFK data in 2014,
19% of LDASA users 60 years or older in the Netherlands
did not have PPI co-medication. This percentage rose from
8.6% (60–69 years) to 13.8% (70–79 years) to 22.1%
(C80 years). Implementing the use of PPI co-medication
resulted in a budget impact of €1,280,477.
4 Discussion
PPI co-medication in LDASA users at risk of UGI adverse
effects appeared to be cost effective, even when costs
caused by potential PPI adverse effects were taken into
account. However, the WTP threshold for a 50% chance of
cost effectiveness for 80-year-old patients was about
€80,000 per QALY. In the base case the same threshold
was reached at a WTP of less than €20,000 per QALY.
This clearly shows that LDASA users older than 60 years
cannot be considered a homogenous group regarding the
cost effectiveness of care strategies. The ICUR for costs
per QALY gained increased correspondingly with age: for
80 years and older patients the costs were 383% higher
than for 60- to 69-year-olds and 337% higher than the base
case. However, when adverse effects were not taken into
account, the strategy of PPI co-medication appeared to be a
‘dominant’ strategy (lower costs and more effect) com-
pared with no PPI in patients 80 years and older. In this
respect, the results of the present study are in line with
those of a previous study [29]. For the base case of 60- to
69-year-old patients, PPI co-medication was found to be
cost effective at a threshold of €10,000 per QALY gained,
comparable with the €13,000/QALY in the present study.
The higher costs in the present study are brought about by
costs for PPI adverse effects.
Differences between the age categories were mainly
caused by the consequences of PPI adverse effects, which
had a higher impact in the older age categories. Since PPI
co-medication in LDASA users is intended for long-term
use, costs for potential adverse effects should be taken into
account [40]. The evidence that long-term PPI use
increases the risk of pneumonia and hip fractures is still
inconclusive and a matter of debate [10, 13–23, 25, 26].
Table 1 Cost effectiveness for the strategy of proton pump inhibitor co-medication compared with no proton pump inhibitor use in low-dose
acetylsalicylic acid users for different age categories and sensitivity analysis for the influence of proton pump inhibitor adverse effects
Age category Costs (€) Incremental costs (€) QALYs Incremental QALYs ICUR (€)
PPI No PPI PPI No PPI
Complete model with both adverse effects
60 years 521.35 438.39 82.96 4.702 4.695 0.006 13,264
70 years 961.48 860.97 100.51 4.550 4.543 0.007 14,671
80 years 2733.31 2457.71 275.59 4.041 4.036 0.004 64,121
Model with only adverse effect pneumonia
60 years 511.70 438.39 73.31 4.702 4.695 0.006 11,360
70 years 921.68 860.97 60.71 4.551 4.543 0.008 7745
80 years 2534.66 2457.71 76.94 4.046 4.036 0.009 8441
Model with only adverse effect hip fracture
60 years 506.10 438.39 67.71 4.702 4.695 0.006 10,620
70 years 914.17 860.97 53.20 4.550 4.543 0.007 7223
80 years 2634.41 2457.71 176.70 4.043 4.036 0.006 28,046
Model with no adverse effects
60 years 496.45 438.39 58.06 4.702 4.695 0.007 8830
70 years 874.35 860.97 13.39 4.551 4.543 0.008 1602
80 years 2435.55 2457.71 –22.16 4.048 4.036 0.011 ‘Dominates’
ICUR incremental cost-effectiveness ratio, PPI proton pump inhibitor, QALYs quality-adjusted life-years
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Fig. 2 Monte-Carlo simulations and cost-effectiveness acceptability
curves for proton pump inhibitor (PPI) co-medication in low-dose
acetylsalicylic acid (LDSA) users at increased upper gastrointestinal
risk. Panels in the left column (a, c, e): scatterplots that present the
results of the Monte-Carlo simulations. One dot represents one
iteration of the Monte-Carlo simulation. The Y-axis states the
incremental costs of adding a PPI compared with no PPI. The X-
axis represents the incremental quality-adjusted life-years (QALYs)
of a PPI compared with no PPI. Panels in the right column (b, d, f):
cost-effectiveness analysis (CEA) curves. The probability that the
incremental costs per QALY are less than or equal to the cost-
effectiveness thresholds of the X-axis is stated on the Y-axis
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Therefore, sensitivity analyses were performed to show the
separate effects of assumptions on the chance of potential
adverse effects for the NMB on the cost effectiveness of
PPI co-medication for the base case and for 80 years and
older patients (Fig. 3). These analyses showed high
uncertainties for the likelihood of adverse effects for both
age categories. The uncertainties for costs due to pneu-
monia and hip fractures were higher for patients 80 years
and older. This can be explained by higher basal risk levels
of hip fracture and pneumonia in very old patients: even a
small risk increase due to PPI use causes a substantial
increase in effect compared with younger age categories.
Adding PPI co-medication to Dutch LDASA users at
UGI risk without actual gastroprotection (19% of all users)
on the basis of this strategy in 2014 would have resulted in
a BIA for 1 year of €1,280,478. The data also suggest that
measures to enhance guideline adherence to prescribe
gastroprotective medication in LDASA users, including the
introduction of a Health Care Inspectorate indicator for
community pharmacists in 2011, has led to a considerable
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Fig. 3 Tornado diagram of the one-way sensitivity analysis for the
effects of different assumptions for the risks and costs of the adverse
effects: base case (a) and 80-year-old low-dose acetylsalicylic acid
users (b). A high parameter value means that a higher parameter value
(95th percentile of the confidence interval from the deterministic
value) was chosen than the deterministic value for the analysis, and
vice versa for a low parameter value (5th percentile). PPI proton
pump inhibitor
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increase in the use of gastroprotective medication and of
PPIs in particular in recent years [8, 9, 30]. In this respect,
pharmacist-led interventions aimed at initiating PPI treat-
ment have been found to be effective instruments in tack-
ling under prescription [41–44].
The present study has several strengths. In contrast to
earlier cost-effectiveness studies, the present study focused
on both PPI benefits and risks in older LDASA users at risk
of UGI adverse effects and compared the strategy of PPI
co-medication with no PPI use. Thus, adverse effects
attributable to long-term PPI use were taken into account.
As the strength of evidence for the two main adverse
effects for PPIs differs, sensitivity analyses were applied to
elucidate their influence on our results. Campylobacteriosis
was not considered because the incidence is much lower
than the modelled adverse effects. In addition, the evidence
on campylobacteriosis is weaker and the related expenses
are also less pronounced. Furthermore, the analyses were
performed for three different age categories of LDASA
users at increased UGI risk according to actual recom-
mendations. Finally, whenever possible the risks were
modelled time and age dependently.
There are also a number of caveats and limitations. First,
we assumed the risks for PPI co-medication to result from
continuous use during 5 years at a compliance rate of 68%
as a reflection of actual clinical practice. In the case of a
lower compliance rate of 20%, the impact of PPI adverse
effects would have been lower but LDASA-induced
adverse effects would have been higher, resulting in an
ICUR of €73,286 for the base-case analysis. In the case of a
higher compliance rate of 100%, the reverse would apply,
resulting in an ICUR of €9391 for the base-case analysis.
However, according to the ICURs, the influence of
LDASA-induced adverse effects seems to be much higher
than that of PPI adverse effects. In addition, full adherence
was assumed for LDASA use. This may have led to an
overestimation of the preventable risks of PPI use. How-
ever, one must take patients’ actual adherence to treatment
into account when interpreting the study results.
Second, only the increased risks of hip fractures was
included, whereas PPI might also increase the risks of other
fractures. Thus, the risk of PPI-induced adverse effects may
have been underestimated, potentially leading to an over-
estimation of the cost effectiveness of PPI co-medication.
Third, as with all similar modelling studies, the present
study is limited by the assumptions made in the model.
Risk ratios for developing adverse effects were collected
from heterogeneous observational studies in the absence of
randomised clinical trial data. However, by preferentially
using meta-analyses and studies published in high-quality
journals, the model was constructed as accurately as
possible.
Fourth, a discount rate of 4.0% for costs and 1.5% for
effects was used in this study. In the literature, there is
considerable debate about the use of discount rates, their
height, and also about the difference between the rates
for costs and effects [32]. The scenario analysis showed
that when a discount rate of 4% was applied to both
outcomes, the resulting ICURs slightly increased
because of fewer effects gains and somewhat lower
incremental effects. Using a rate of 1.5% for both out-
comes also led to higher ICURs (not shown here) than in
the base-case scenario.
Finally, with respect to the BIA, it is important to note
that the prices used to calculate the BIA reflect the real
prices used by the healthcare insurers. At present in the
Netherlands these prices are rather low due to the power of
health insurers to impose stiff price-restricting measures
that may differ by insurer and are not fully transparent. We
believe that the prices used in the present study are the best
available under these circumstances.
5 Conclusion
For LDASA users between 60 and 80 years of age at
increased risk of UGI adverse effects, the use of PPI co-
medication is likely to be a cost effective approach, even
when PPI-induced adverse effects are taken into account.
However, with increasing age the cost effectiveness
declines, predominantly due to increased risks for PPI-in-
duced adverse effects.
Table 2 Budget impact analysis (BIA) after 1 year for proton pump inhibitor co-medication in those low-dose acetylsalicylic acid users at
increased upper gastrointestinal risk without proper co-medication in The Netherlands
Age category Absolute numbers of
LDASA users at UGI risk
Cost difference between
PPI and no PPI addition (€)
Total BIA of
implementing PPI (€)
60–69 years 1300 –22.39 –29,107
70–79 years 14,126 17.28 244,097
C80 years 55,610 19.16 1,065,488
All C60 years 71,036 1,280,478
BIA budget impact analysis, LDASA low-dose acetylsalicylic acid, PPI proton pump inhibitor, UGI upper gastrointestinal
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Table 3 Acetylsalicylic acid model
Parameter (3-month cycles) Probability 95% CI Source
Strategy dependent
Probability to develop dyspepsia 0.026 0.01–0.04 [29]
Probability to develop PUB Age and cycle
dependent
[34]
Probability that dyspepsia resolves 0.5 0.45–0.55 [45]
Probability to develop dyspepsia post-GI bleeding 0.05 0.01–0.07 [30]
Probability that dyspepsia resolves post-GI bleeding 0.61 0.55–0.68 [30]
Probability of re-bleeding post-GI bleeding 0.1 0.07–0.17 [30]
Probability of pneumonia due to PPI Age and cycle
dependent
[34]
Probability of hip fracture due to PPI Age and cycle
dependent
[34]
Probability of PPI compliance 0.68 0.2–1 [30]
Risk ratio for pneumonia due to PPI use 1.89 1.36–2.62 [18]
Risk ratio for hip fracture due to PPI use (after 1 year) 1.24 1.15–1.34 [46]
Costs of PPI for 3 months €2.40 2.00–10.00 [33]
Standard prescription costs €6.00 [33]
First prescription costs €12.00 [33]
Strategy independent
See lifetables—general mortality rate Age and cycle
dependent
[34]
Chance to die of PUB 0.02 0.010–0.037 [30]
Chance of death due to hip fracture 0.25 0.15–0.35 [47]
Chance of dyspepsia while on ASA 0.050 0.01–0.08 [29]
Chance of PUB while on LDASA Age and cycle
dependent
[34]
Chance of dyspepsia post-GI bleeding (2 9 PPI) = 0.1a [30]
Chance of re-bleeding post-bleeding (2 9 PPI) = 0.2a [30]
Utility for dyspepsia 0.94 0.9–0.98 [29]
Utility for persisting dyspepsia 0.88 0.87–0.93 [29]
Utility for GI bleeding 0.94 0.88–0.97 [29]
Utility post-GI bleeding 0.98 0.95–1 [29]
Utility for dyspepsia post-GI bleeding 0.94 0.9–0.98 [30]
Utility for persisting dyspepsia post-GI bleeding 0.88 0.87–0.93 [30]
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